FDA Approves PALONOSETRON — Fresenius Kabi USA, LLC

Fresenius Kabi USA, LLC announced the approval of generic palonosetron hydrochloride by the FDA on September 19, 2018, offering a less expensive alternative to branded preventive antiemetics. This launch is strategically positioned to capitalize on market share, particularly as patent expirations for leading competitors create significant pricing pressure in the oncology treatments sector.